Unquoted Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SnowShredder who wrote (27)	1/13/2002 12:10:15 AM
From: SnowShredder	Read Replies (2) of 253

Just parking...Best of Luck, SS >>> intragene.com The enormous promise of human gene therapy has been limited in recent years by the lack of efficient and specific gene delivery systems. At IntraGene Sciences, we are pioneering the development of a new range of gene delivery methods that will improve both the efficiency and specificity of gene delivery. These technologies have application to human gene therapy, cell engineering, and transgenic animal production. Our current technology platform includes: HyVec: a novel hybrid vector containing the best characteristics of both adenovirus and retrovirus vector systems. RepliVec: a replication-competent retrovirus vector that is capable of proliferating specifically in cancer cells and thereby delivering therapeutic genes throughout an entire tumor mass. CorrolVec: Targeted drug delivery to specific sites in the body following systemic administration. DCVec: Gene delivery to dendritic cells for stimulation of an anti-cancer immune response.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next